{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"12"}]}],"title":"AE Severity (Mild)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"10"}]}],"title":"AE Severity (Moderate)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"AE Severity (Severe)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"AE Relationship to Drug (Not related)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"}]}],"title":"AE Relationship to Drug (Probably not related)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}]}],"title":"AE Relationship to Drug (Possibly related)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"}]}],"title":"AE Relationship to Drug(Probably related)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}],"title":"AE Relationship to Drug (Definitely related)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"description":"Number of participants with treatment emergent adverse events (TEAEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related').","groups":[{"description":"Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"Non-Hodgkin's Lymphoma (NHL)"},{"description":"Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"Multiple Myeloma (MM)"},{"description":"All patients.","id":"OG002","title":"Total"}],"paramType":"NUMBER","populationDescription":"Safety population - all participants who received at least 1 dose of plerixafor.","reportingStatus":"POSTED","timeFrame":"Day 1 to approximately Day 38 (before start of chemotherapy)","title":"Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE)","type":"PRIMARY","unitOfMeasure":"participants"}